vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and Piedmont Realty Trust, Inc. (PDM). Click either name above to swap in a different company.
Piedmont Realty Trust, Inc. is the larger business by last-quarter revenue ($143.3M vs $86.8M, roughly 1.7× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 0.4%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 0.0%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Piedmont Realty Trust, Inc. is a publicly traded real estate investment trust (REIT) that owns, operates, and invests in high-quality office properties primarily located in high-growth metropolitan areas across the United States. It serves corporate tenants across multiple industry sectors including technology, professional services, and healthcare, and pursues stable long-term returns for stakeholders via strategic property management and portfolio optimization.
IOVA vs PDM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $143.3M |
| Net Profit | — | $-45.0M |
| Gross Margin | 67.4% | — |
| Operating Margin | -84.7% | — |
| Net Margin | — | -31.4% |
| Revenue YoY | 17.7% | 0.4% |
| Net Profit YoY | — | -27.9% |
| EPS (diluted) | — | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $143.3M | ||
| Q4 25 | $86.8M | $142.9M | ||
| Q3 25 | $67.5M | $139.2M | ||
| Q2 25 | $60.0M | $140.3M | ||
| Q1 25 | $49.3M | $142.7M | ||
| Q4 24 | $73.7M | $143.2M | ||
| Q3 24 | $58.6M | $139.3M | ||
| Q2 24 | $31.1M | $143.3M |
| Q1 26 | — | $-45.0M | ||
| Q4 25 | — | $-43.2M | ||
| Q3 25 | $-91.3M | $-13.5M | ||
| Q2 25 | $-111.7M | $-16.8M | ||
| Q1 25 | $-116.2M | $-10.1M | ||
| Q4 24 | — | $-30.0M | ||
| Q3 24 | $-83.5M | $-11.5M | ||
| Q2 24 | $-97.1M | $-9.8M |
| Q1 26 | — | — | ||
| Q4 25 | 67.4% | — | ||
| Q3 25 | 43.0% | — | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 68.7% | — | ||
| Q3 24 | 46.2% | — | ||
| Q2 24 | -0.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | -84.7% | — | ||
| Q3 25 | -140.7% | — | ||
| Q2 25 | -189.8% | — | ||
| Q1 25 | -245.8% | — | ||
| Q4 24 | -117.5% | — | ||
| Q3 24 | -152.1% | — | ||
| Q2 24 | -327.6% | — |
| Q1 26 | — | -31.4% | ||
| Q4 25 | — | -30.3% | ||
| Q3 25 | -135.3% | -9.7% | ||
| Q2 25 | -186.2% | -12.0% | ||
| Q1 25 | -235.5% | -7.1% | ||
| Q4 24 | — | -20.9% | ||
| Q3 24 | -142.7% | -8.3% | ||
| Q2 24 | -312.2% | -6.8% |
| Q1 26 | — | $-0.10 | ||
| Q4 25 | — | $-0.34 | ||
| Q3 25 | — | $-0.11 | ||
| Q2 25 | $-0.33 | $-0.14 | ||
| Q1 25 | $-0.36 | $-0.08 | ||
| Q4 24 | $-0.24 | $-0.25 | ||
| Q3 24 | $-0.28 | $-0.09 | ||
| Q2 24 | $-0.34 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $2.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $1.5B |
| Total Assets | $913.2M | $4.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $2.3M | ||
| Q4 25 | $297.0M | $731.0K | ||
| Q3 25 | $300.8M | $3.0M | ||
| Q2 25 | $301.2M | $3.3M | ||
| Q1 25 | $359.7M | $2.9M | ||
| Q4 24 | $323.8M | $109.6M | ||
| Q3 24 | $397.5M | $133.6M | ||
| Q2 24 | $412.5M | $138.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $2.2B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | — | $2.2B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B |
| Q1 26 | — | $1.5B | ||
| Q4 25 | $698.6M | $1.5B | ||
| Q3 25 | $702.3M | $1.5B | ||
| Q2 25 | $698.5M | $1.5B | ||
| Q1 25 | $767.9M | $1.6B | ||
| Q4 24 | $710.4M | $1.6B | ||
| Q3 24 | $773.5M | $1.6B | ||
| Q2 24 | $768.5M | $1.7B |
| Q1 26 | — | $4.0B | ||
| Q4 25 | $913.2M | $4.0B | ||
| Q3 25 | $904.9M | $4.0B | ||
| Q2 25 | $907.4M | $4.0B | ||
| Q1 25 | $966.7M | $4.0B | ||
| Q4 24 | $910.4M | $4.1B | ||
| Q3 24 | $991.1M | $4.1B | ||
| Q2 24 | $964.3M | $4.2B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.49× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | — | 1.41× | ||
| Q1 25 | — | 1.40× | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | — | 1.36× | ||
| Q2 24 | — | 1.34× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | — |
| Free Cash FlowOCF − Capex | $-61.9M | — |
| FCF MarginFCF / Revenue | -71.3% | — |
| Capex IntensityCapex / Revenue | 10.7% | 110.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-52.6M | $140.6M | ||
| Q3 25 | $-78.7M | $35.8M | ||
| Q2 25 | $-67.4M | $50.1M | ||
| Q1 25 | $-103.7M | $3.7M | ||
| Q4 24 | $-73.3M | $198.1M | ||
| Q3 24 | $-59.0M | $42.9M | ||
| Q2 24 | $-98.4M | $66.8M |
| Q1 26 | — | — | ||
| Q4 25 | $-61.9M | — | ||
| Q3 25 | $-89.5M | — | ||
| Q2 25 | $-74.9M | — | ||
| Q1 25 | $-109.9M | — | ||
| Q4 24 | $-77.5M | — | ||
| Q3 24 | $-61.3M | — | ||
| Q2 24 | $-98.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | -71.3% | — | ||
| Q3 25 | -132.7% | — | ||
| Q2 25 | -124.9% | — | ||
| Q1 25 | -222.8% | — | ||
| Q4 24 | -105.1% | — | ||
| Q3 24 | -104.6% | — | ||
| Q2 24 | -317.9% | — |
| Q1 26 | — | 110.3% | ||
| Q4 25 | 10.7% | — | ||
| Q3 25 | 16.1% | — | ||
| Q2 25 | 12.4% | — | ||
| Q1 25 | 12.6% | — | ||
| Q4 24 | 5.7% | — | ||
| Q3 24 | 3.9% | — | ||
| Q2 24 | 1.4% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
PDM
Segment breakdown not available.
